Kura Oncology, Inc. (NASDAQ:KURA) Receives $25.11 Consensus Price Target from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $24.1429.

Several equities research analysts recently issued reports on KURA shares. UBS Group upped their price target on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Wednesday, October 8th. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 5th. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, October 20th. Finally, Guggenheim assumed coverage on shares of Kura Oncology in a research note on Thursday, September 4th. They set a “neutral” rating on the stock.

Insiders Place Their Bets

In related news, insider Teresa Brophy Bair sold 8,804 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $98,428.72. Following the completion of the transaction, the insider owned 188,139 shares in the company, valued at $2,103,394.02. The trade was a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,539 shares of the stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $50,746.02. Following the completion of the sale, the senior vice president directly owned 130,257 shares in the company, valued at $1,456,273.26. This represents a 3.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 122,675 shares of company stock worth $1,196,657. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after purchasing an additional 3,072 shares during the period. State of Wyoming acquired a new stake in Kura Oncology in the 1st quarter valued at approximately $48,000. PNC Financial Services Group Inc. raised its stake in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after acquiring an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares in the last quarter. Finally, Pallas Capital Advisors LLC boosted its position in Kura Oncology by 32.2% during the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after acquiring an additional 3,241 shares during the period.

Kura Oncology Stock Performance

Shares of KURA stock opened at $11.17 on Thursday. The stock has a market capitalization of $972.01 million, a price-to-earnings ratio of -4.50 and a beta of 0.35. Kura Oncology has a one year low of $5.41 and a one year high of $12.49. The company’s 50-day simple moving average is $9.74 and its 200-day simple moving average is $7.65. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Equities analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.